Quantum-Si (NASDAQ:QSI) Announces Earnings Results, Beats Estimates By $0.06 EPS

Quantum-Si (NASDAQ:QSI) posted its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06, FiscalAI reports. Quantum-Si had a negative net margin of 4,160.06% and a negative return on equity of 43.24%. The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.76 million.

Here are the key takeaways from Quantum-Si’s conference call:

• Quantum-Si calls 2026 a deliberate “transition year” with total revenue guidance of approximately $1.0M, expecting very modest capital sales and revenue driven primarily by consumable utilization as the company prioritizes market preparation for Proteus.
• The company announced a list price of $425,000 for Proteus, says prototypes outperform the current system across key metrics, and expects instrument development to be on track for an end‑of‑2026 commercial launch with detection of 18 amino acids at launch and demonstration of all 20 during 2026.
• A capital‑efficient placement program has added 17 new customers, increased consumable run rates (management expects >25% consumable kit volume growth baked into 2026 guidance), and helped build a publication pipeline—early 2026 releases include clinical proteomics and rapid pathogen detection use cases.
• The balance sheet remains strong with $215.8M in cash and marketable securities at year‑end; management guided adjusted operating expenses ≤ $98M and total cash usage ≤ $93M for 2026, projecting runway into Q2 2028 to fund Proteus completion and commercial readiness.
• Recent financials show Q4 revenue of $451K and FY2025 revenue of $2.4M (Q4 gross margin 27%, FY gross margin 47%), with margins and Q4 results impacted by a higher consumable mix and inventory adjustments; management highlights year‑over‑year reductions in adjusted OpEx driven by cost discipline.

Quantum-Si Trading Down 4.0%

Quantum-Si stock opened at $0.91 on Thursday. Quantum-Si has a 12 month low of $0.89 and a 12 month high of $3.10. The stock has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.37. The firm has a market cap of $196.10 million, a price-to-earnings ratio of -1.75 and a beta of 3.00.

Analyst Ratings Changes

A number of brokerages have issued reports on QSI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a research note on Monday, December 29th. Canaccord Genuity Group set a $1.00 price target on Quantum-Si in a report on Wednesday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.25.

Insider Buying and Selling at Quantum-Si

In related news, insider John S. Vieceli sold 21,927 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $1.28, for a total transaction of $28,066.56. Following the sale, the insider directly owned 800,973 shares of the company’s stock, valued at $1,025,245.44. This trade represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey Alan Hawkins sold 23,707 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $1.28, for a total transaction of $30,344.96. Following the transaction, the chief executive officer owned 2,578,018 shares in the company, valued at $3,299,863.04. This represents a 0.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 54,261 shares of company stock worth $69,454 over the last ninety days. 30.04% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Quantum-Si

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock valued at $131,000 after purchasing an additional 9,005 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Quantum-Si by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,082 shares of the company’s stock worth $96,000 after acquiring an additional 10,564 shares during the period. Prudential Financial Inc. bought a new stake in Quantum-Si during the 2nd quarter worth approximately $25,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Quantum-Si by 23.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after purchasing an additional 13,546 shares in the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Quantum-Si in the second quarter worth approximately $29,000. 39.90% of the stock is owned by institutional investors.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.